BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Dana-Farber and Deerfield Join Forces Again in $130 Million Collab

  The duo launch Riverway Discoveries to drive the development and commercialization of new cancer therapeutics faster into patient’s hands.

  February 8, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  FDA

  New Hope for B-Cell Lymphoma Patients as FDA Approves BMS’ CAR-T Therapy

  Bristol Myers picked up the therapy when it acquired Celgene in 2019 for $74 billion.

  February 8, 2021

   · 

  3 min read

   · 

  Mark Terry
• Stem Cell Therapy Market: Top 5 trends fueling the industry revenue through 2025

  The global stem therapy market growth will be driven by extensive R&D activities aimed at developing novel therapies and personalized medicines.

  February 8, 2021

   · 

  4 min read
• 

  Policy

  In Consultation with FDA, Freeline Modifies Hemophilia B Gene Therapy Trial

  London-based Freeline Therapeutics announced that after receiving feedback from the U.S. Food and Drug Administration (FDA), it was modifying its clinical trial program for FLT180a for Hemophilia B.

  February 8, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  SEC Slaps Biotech Consultant Mark Ahn with Insider Trading Charges

  A Portland, Oregon biotech consultant is facing two counts of insider trading charges, with federal prosecutors and securities regulators claiming the defendant made profitable stock trades using confidential information he learned during his time consulting for Abeona Therapeutics.

  February 8, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Drug Development

  2021 Biopharma Update on the Novel Coronavirus: February 9

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.

  February 8, 2021

   · 

  6 min read

   · 

  BioSpace Editorial Staff
• 

  Job Trends

  South Africa Pauses AstraZeneca Vaccine Rollout Over Small but Dismal Study Results

  South Africa has delayed the distribution of the AstraZeneca-University of Oxford COVID-19 vaccine after data suggested it “provides minimal protection” against mild disease from the South African variant.

  February 8, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  Avrobio Gene Therapy Shows Early Promise in Fabry, Other Rare Lysosomal Diseases

  Shares of Avrobio were up nearly 20% in premarket trading after the company posted positive clinical data from its gene therapy trials in three different rare lysomal diseases, Fabry, Gaucher type 1 and cystinosis.

  February 8, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Deals

  Gemini Therapeutics Hits the Nasdaq Following SPAC Merger

  The combined company will be called Gemini Therapeutics, Inc. and will trade under the ticker symbol, GMTX.

  February 8, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Former Biogen CEO Takes the Helm at Editas Medicine

  James C. Mullen succeeds Cynthia Collins as Editas’ CEO, effective on February 15, 2021.

  February 8, 2021

   · 

  2 min read

   · 

  Brandon May